About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Study Says Malaria Vaccine Fails to Work After Four Years

by Sheela Philomena on March 21, 2013 at 10:02 AM
Font : A-A+

 Study Says Malaria Vaccine Fails to Work After Four Years

A new malaria vaccine seems to stop working in kids after four years, says research.

The vaccine candidate -- known as RTS,S -- is not yet on the market, but ongoing trials in seven African countries generated hope that it might help slow new malaria cases as drug resistance to the deadly parasite grows.

Advertisement

One child in Africa dies every minute from malaria, a mosquito-borne disease that kills an estimated 655,000 people every year. There is currently no vaccine available that offers full protection against it.

The latest data comes from a phase II follow-up study on 320 children in Kenya which found that in the first year after vaccination, protection against malaria was 43.6 percent, but that dropped to zero by the fourth year.
Advertisement

It also found that the more often a child was exposed to malaria, the less effective the vaccine appeared to be.

The vaccine's efficacy was 45.1 percent in children with below-average exposure to malaria, but just 15.9 percent in children with above-average exposure, said the study, published in the New England Journal of Medicine.

"Despite the falling efficacy over time, there is still a clear benefit to the vaccine candidate," said senior author Phillip Bejon.

"We now need to look at whether offering a vaccine booster can sustain efficacy for longer," added Bejon, a fellow at the KEMRI-Wellcome Trust Research Programme and the Centre for Tropical Medicine, University of Oxford.

Early results from larger, ongoing phase III trials have shown the vaccine cut malaria cases in half during the first year of follow-up in young children, and by about a third in babies.

Mary Anne Rhyne, a US spokeswoman from GlaxoSmithKline, the pharmaceutical company that makes the vaccine, said the Kenya study is "small" and uses data from just one of many trial sites, while larger studies are still under way.

"The Phase III pivotal study, involving 15,460 children, is ongoing and should provide meaningful insights into the vaccine candidate's efficacy in different malaria parasite transmission settings, longer-term efficacy (2.5 years after primary vaccination) and the impact of a booster dose," she told AFP in an email.

"These analyses are expected to be publicly available by the end of 2014."

In the meantime, she said, the vaccine is "still under development and subject to the evaluation of its benefits and risks by the regulatory authorities before being made available."

In November 2012, results from phase III tests on 6,500 infants showed that the RTS,S vaccine only protected about a third of very young babies, compared to success rates of between 47 percent and 55 percent in children between the ages of five and 17 months.

At the time, GSK's chief executive officer Andrew Witty described those results as "a little frustrating."

The RTS,S vaccine candidate trial is the largest of its kind, and is being conducted at 11 sites across seven African countries.

There are several other projects under way with vaccine candidates in clinical trials worldwide.

Separately on Wednesday, a group of international researchers announced progress in studies on mice that could lead to a new malaria vaccine candidate for humans, one that appears not to create drug resistance in the parasites.

"This is one of the first drugs ever to kill the malaria parasite in all three stages of its life cycle," said Dennis Kyle of the University of San Francisco College of Public Health's Global Infectious Diseases Research team.

The drug, called ELQ-300, is being prepared for clinical trials, according to the research published in the journal Science Translational Medicine.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Malaria-water Malaria Mosquito Diseases Vaccination for Children Fever Top 10 Vaccine Myths Debunked Malaria - Protection Strategies 

Recommended Reading
Malaria
Malaria is caused by a parasite that enters blood through the bite of an infected mosquito. It is .....
Mosquito Diseases
Mosquito-borne diseases, like malaria, filaria, dengue, etc are common in places conducive of ......
Quiz on Malaria
Malaria is a common parasitic disease of the tropics, resulting in a million deaths every year. ......
Insecticide-treated Bed Nets Could Eradicate Malaria
Use of bed nets treated with insecticides was found to eliminate malaria, suggests study....
Fever
Fever or Pyrexia is an elevation in normal body temperature. Causes of fever include infections, inj...
Malaria - Protection Strategies
Malaria is a dangerous disease with lethal consequences that requires protective measures for preven...
Top 10 Vaccine Myths Debunked
Childhood vaccination has saved many lives, yet lots more has to be done to increase awareness and e...
Vaccination for Children
Vaccines are biological products that impart immunity to the recipient. Vaccines may be live attenua...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use